Combination of shikonin and gefitinib reverses drug resistance in human non-small cell lung cancer and its mechanism
The occurrence and development of tumors are associated with the cell energy metabolism.Inhibiting energy metabolism of lung cancer cells is an important strategy to overcome drug resistance.Based on the cellular energy metabolism pathway,this study observed the effect of combination of shikonin(SKN)and gefitinib(GFB)on the drug resistance in non-small cell lung cancer and explored the underlying mechanism.The human non-small cell lung cancer line HCC827/GR resistant to gefitinib was used as the cell model in vitro.The CCK-8 assay and flow cytometry were employed to investigate the cell viability and apoptosis,respectively.The high performance liquid chromatography was employed to measure the intracellular accumulation of GFB.A Seahorse XFe96 Analyzer was used to detect the changes of cellular energy metabolism.Western blot was employed to determine the expression of the proteins involved in the drug resistance.The tumor-bearing nude mouse model was used to verify the efficacy of SKN+GFB in overcoming drug resistance in vivo.The results showed that SKN+GFB significantly reduced the IC50 of GFB on HCC827/GR cells,with the combination index of 0.628,indicating that the combination of the two drugs had a synergistic effect and promoted cell apoptosis.SKN increased the intracellular accumulation of GFB.SKN+GFB lowered the oxygen consumption rate(OCR)and glycolytic proton efflux rate(GlycoPER)in cell energy metabolism,and down-regulated the overexpression of PKM2,p-EGFR,P-gp,and HIF-1α in drug resistance.The results of reversing drug resistance test in vivo showed that GFB or SKN alone had no significant antitumor effect,while the combination at different doses induced the apoptosis of the tumor tissue and inhibited the expression of PKM2 and P-gp,demonstrating a significant antitumor effect.Moreover,the tumor inhibition rate in the high-dose combination group reached 64.01%.In summary,SKN+GFB may interfere with the energy metabolism to limit the function of HCC827/GR cells,thus reversing the GFB resistance in non-small cell lung cancer.
NETL
